Summary
Quest Diagnostics Incorporated (DGX) announced on December 9, 2019, the pricing of an $800 million public offering of 2.950% senior notes due 2030. The company expects to receive the net proceeds from this offering on December 16, 2019, subject to standard closing conditions. This action is part of the company's strategy to manage its debt obligations. These new notes are intended to refinance existing debt, specifically to repay or redeem its 4.750% senior notes due 2020 and 2.500% senior notes due 2020. The remaining proceeds will be used for general corporate purposes. This debt refinancing is a key financial event that could impact the company's interest expense and overall capital structure, offering a potential benefit through a lower coupon rate on the new debt compared to the maturing notes.
Key Highlights
- 1Quest Diagnostics priced an $800 million public offering of 2.950% senior notes due 2030.
- 2The new notes are expected to be issued under the company's existing shelf registration statement.
- 3Proceeds are slated to be used for repaying or redeeming 4.750% senior notes due 2020 and 2.500% senior notes due 2020.
- 4The company also intends to use net proceeds for general corporate purposes.
- 5The closing of the offering is anticipated on December 16, 2019, subject to customary conditions.
- 6The company entered into an underwriting agreement with J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, and Wells Fargo Securities, LLC.
- 7This filing is not a notice of redemption for the existing notes; separate notices will be issued if redemption occurs.